FibroGen China

About FibroGen China

FibroGen (China) Pharmaceutical Technology Development Co., Ltd. is a Beijing‑based biotech company founded in 2011 that focuses on developing first‑in‑class innovative drugs and medical devices for unmet clinical needs in China. The firm’s flagship product, AiriZhuo® (roxadustat capsules), is a HIF‑pathway inhibitor approved for anemia in chronic kidney disease and represents a breakthrough in novel mechanism therapy. FibroGen China operates a formulation plant in Beijing Economic‑Technical Development Zone, a raw‑material facility in Cangzhou, Hebei, and has subsidiaries in Shanghai and Cangzhou, integrating global R&D with a China‑first strategy.